Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)–A discrete choice experiment
These results document considerable preference similarities among cardiologist and PCP prescribers of LDL-C lowering therapies for ASCVD. Broad availability of several therapies with varying administration frequencies and product profiles are likely of great value to prescribing physicians aiming to achieve target LDL-C concentrations. Considering all aspects of treatment, most participants preferred a PCSK9 siRNA-like drug.
Authors
- Laetitia N’Dri
- Marlon Graf (ORCID: https://orcid.org/0000-0002-6240-8867)
- Sukyung Chung (ORCID: https://orcid.org/0000-0001-6906-2320)
- Amit V. Khera (ORCID: https://orcid.org/0000-0001-6535-5839)
- Suepattra G. May (ORCID: https://orcid.org/0000-0002-7228-8440)
- Batul Electricwala
- Joaquim Cristino
Institutions
- Brigham and Women's Hospital (US)
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Verve Therapeutics (United States) (US)
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e35990
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Novartis Pharmaceuticals Corporation